FDA Approps Amendment Targets Chief Counsel Troy

FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts

More from Archive

More from Medtech Insight

AI-Powered Robotics: Monogram Bets On ‘Active’ Assistance With FDA-Cleared Robotic Knee System To Outperform Stryker’s Haptics

 
• By 

Beyond the US market, Monogram is actively pursuing regulatory approvals abroad, with India as a key target. The company has partnered with Shalby Hospitals, one of India’s largest orthopedic hospital networks, to conduct clinical trials and accelerate regulatory clearance in the region.

Dexcom’s Jake Leach And Adrian Gut Discuss Strategy For CGM Growth, Reimbursement, AI Integration And Policy Challenges

 
• By 

In an interview with Medtech Insight, Dexcom’s COO Jake Leach and Adrian Gut, senior director international access, discuss the company’s global expansion, the role of AI in diabetes management, the challenges of securing reimbursement, and how regulators are influencing the future of CGM technology.